Telomir Pharmaceuticals, Inc. announced the peer-reviewed publication of preclinical data for Telomir-Zn in Biomedicine & Pharmacotherapy, demonstrating dose-dependent improvements in glucose homeostasis and insulin resistance in a zebrafish model of Type 2 diabetes. The findings support the mechanism of action for Telomir-Zn, which has received FDA IND clearance for a Phase 1/2 clinical trial in triple-negative breast cancer. Telomir Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing clinical-stage lead programs.

Telomir Pharmaceuticals, Inc. appointed Andriy Mushak as its fractional Chief Financial Officer, effective June 6, 2026, replacing Alan Weichselbaum. Mr. Mushak will be paid $6,000 per month for his services through a consulting agreement with LMAM Consulting Group, LLC.